without prothrombotic defects who remained asymptomatic after a course of OCT at young age and then became symptomatic during a second course of OCT at an older age. To our knowledge, this is the first study of this type that clearly demonstrates the role of age in the pathogenesis of OCT-associated venous thrombosis.
PATIENTS AND METHODS
All consecutive female patients who were fertile seen in our outpatient clinic or investigated in our laboratory from January 1990 to December 31, 2002 were considered. A total of approximately 2800 patients were studied. Approximately 950 of these patients had taken, for some time during their lifetime, OCT or were taking the medication at the time of study.
All patients who had two well-documented courses of OCT in two different periods of their life were selected. Thirty-one patients were found to meet these criteria. However, three patients had to be excluded because they had other associated risk factors besides coagulation defects and OCT at the time of thrombosis. Fourteen of these women presented a congenital coagulation defect, one patient had an acquired condition (antiphospholipid antibody syndrome), and the remaining 13 patients were normal women (Tables 1 and 2) .
All other known prothrombotic conditions were excluded by accepted procedures in both groups of subjects.
The oral contraceptive courses were documented directly in 26 of the 28 patients or subjects because they had been observed in our outpatient clinic approximately every 6 months during both courses of therapy.
Two normal women have not been observed by us during the first course of OCT period but were seen by us at the time of thrombosis.
In women with a prothrombotic condition, the diagnosis was made, in every instance, during or immediately after the first course of OCT. All patients were duly informed about the defect and its potential cause for a thrombotic event. They chose to receive the medication due to the fact that they had remained thrombosis-free during the previous course. On the contrary, the women not included in the study had refused to restart OCT when duly informed of the potential prothrombotic condition. The patients with prothrombotic defects were closely evaluated every 3 months during the second course of OCT.
Venous thromboembolism episodes were documented in all cases by objective methods, namely compressive ultrasonography (CUS) and/or phlebography. Patients suspected to have pulmonary embolism underwent perfusion-ventilation scan and/or spiral computed tomography.
Factor V Leiden evaluation both from a clotting and genetic analysis point of view was carried out as previously described (18) . Protein S complete evaluation (total free and bound) was also carried out as reported both as activity and antigen (19) . Antiphospholipid antibody assessment was carried out according to accepted procedures, which included confirmation tests.
RESULTS
The mean age at which thrombosis occurred was 33.3 years in the case of patients with prothrombotic defects and of 36.3 years in apparently normal women. During the second course of OCT, thrombosis occurred after a mean duration of 6.5 months or cycles in the patients with coagulation defects and after 18.4 months in normal women.
The mean ages during which women remained asymptomatic during the first course of OCT were 23.1 and 23.3 years for women with or without prothrombotic conditions, respectively. The median value of the age range during which some women took OCT was used for these calculations. During the asymptomatic course, at young age, 15 women took preparations containing old progestins whereas 13 took those with third-generation compounds, gestodene or desogestrel. One woman (case 1A) took, during the asymtomatic phase, both old or third-generation progestins. She was placed in the old progestins group because these drugs were used for a longer time. On the contrary, during the symptomatic course, at older age, only seven women were taking old progestins whereas the majority, 21 subjects, were on preparations containing third-generation compounds. The type of venous thromboembolism varied. Eighteen women had deep venous thrombosis (DVT) of their legs, one woman had DVT of her leg and pulmonary embolism (PE), two had PE, three women had DVT of their upper limbs, one had thrombosis of both a leg and an arm, one had central retinal vein thrombosis, and another had cerebral sinuses thrombosis. No important difference in the distribution of venous thrombosis was noted between the women with defects and those without defects. 
DISCUSSION
Age is known to be associated with an increased incidence of venous thrombosis with or without pulmonary embolism (13) (14) (15) (16) (17) . This was demonstrated to be true even for women taking oral contraceptives (2, (20) (21) (22) . After all, the age range of fertility is quite wide in women, varying from 15-16 to 50-51 years, depending on country, nutrition, general health status, socioeconomic conditions, and so on. These are usually the ages during which OCT is provided. It is known, due to epidemiologic observations, that OCT in older women is more thrombogenic. However, to our knowledge, no comparative study is available, particularly no follow-up study for the same cohort of subjects.
The data here presented clearly show that age plays an important role in the pathogenesis of OCT-associated thrombosis.
Because the majority of patients have been taking, during the second course of OCT, preparations containing third-generation progestins, a role of these compounds cannot be completely excluded. During the first course of OCT, instead, the majority of women took old progestins. This is expected because preparations containing third-generations progestins became widely available in the mid-1990s (19, 20) .
The increased prothombotic role of third-generation progestins has been the object of extensive studies and also of nasty disputes (23) (24) (25) (26) . Altogether it seemed that they indeed possess a slightly more pronounced prothrombotic activity as compared with old progestins (23, 24) .
However, a recent reevaluation of the problem concluded that no major difference exists between the different type of progestins (27) . So this possibility seems unlikely but cannot be completely dismissed.
In this regard, one has to keep in mind that third-generation progestins are now the most widely used compounds. The observed increased incidence in OCT-associated thrombosis could also be simply due, at least in part, to the fact that more women use preparations that contain third-generation progestins. This finding concurs with a recent observation of ours that showed that the prescription pattern of oral contraceptives in a northern Italian province during the past decade has changed considerably in favor of preparations containing new progestins (28) .
The average age at which thrombosis occurred was similar in the two groups of patients (33.3 years vs. 36.3 years, respectively, for women with or without a defect). This could be surmised to indicate that the congenital or acquired prothrombotic conditions played a minor role, if any, in the pathogenesis of venous thrombosis in these patients. An untenable position indeed. In fact, venous thrombosis occurred in women with prothrombotic defects after a shorter number of cycles as compared with women without defects (6.5 vs. 18.4 cycles, respectively). This has been demonstrated to be the case even in other groups of patients (4,8) and indicates that the congenital conditions do play a role, even though a variable one. Such a variability is probably due to the fact that thrombosis may be the result of multigenetic disords interfering with several acquired conditions (29) .
It has been also demonstrated that the average duration of OCT before the appearance of thrombosis seems to vary with the defect. Antithrombin deficiency is supposed to be the most dangerous condition during OCT. The incidence of thrombosis is high and appears after one to two cycles only (4,8). With regard to factor V Leiden, thrombosis seems to appear after an average of 10 to 12 cycles, as in normal women (8).
In view of these results, it is conceivable to prescribe, to elderly women (older than 35?) preparations containing second-generation progestins. It has to be remembered, however, that the preparations that contain old progestins often contain also 50 γ of estradiol. Due to the potential negative effects of a high dosage of estradiol, preparations containing both low estrogen (30 γ) and an old progestin (levonorgestrel) should be chosen, for example Ovranet (Wyeth Lederle) or Ecogyn 30 (Schering) or similar products.
Similar indications have been given for the start or onset of OCT in women who have never been exposed to the medication (first-time users), but this has not been generally accepted (23, 25 
